Last €31.93 EUR
Change Today -0.02 / -0.06%
Volume 43.0K
SAZ On Other Exchanges
Symbol
Exchange
Xetra
OTC US
OTC US
As of 4:09 AM 07/28/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Stadastrasse 2-18

Bad Vilbel, 61118

Germany

Phone: 49 6101 6030

Fax: 49 6101 603 259

Stada-Arzneimittel AG (STADA) operates in the field of marketing active ingredients. The company markets multisource products that is products with active ingredients that are off-patent and free of other commercial property rights. It focuses on off-patent active ingredients, known as ‘multisource products’. It offers doctors, pharmacies and patients a range of products for various indications. The company operates in three segments: Generics, Branded products, and Special pharmaceuticals. The company also engages in non core activities such as commercial business to support or supplement the core segments. Generics Segment Generics are drugs which, after expiration of the patent or other relevant commercial property rights, are offered in the same quality. The Group’s selling active ingredient in the Generics core segment is the stomach medication Omeprazole. In Germany, the Group's generic drugs are marketed under the STADA brand and also by the Group subsidiary ALIUD PHARMA. The range of these two sales lines covers all of the important indications and dosage forms. With generics and branches in Belgium, Denmark, France, the United Kingdom, Ireland, Italy, Kazakhstan, the Netherlands, Austria, Portugal, Russia, Switzerland, Spain, Ukraine and the Czech Republic, STADA represents in European markets with its own sales lines for generics. In the USA also STADA is active in the generics market with its own sales company. Branded Products Segment STADA’s branded products are the drugs or health care products that the Group offers under a product-specific brand name. In this segment, STADA concentrates on multisource products that are accessible without own active ingredient research. The Branded Products portfolio includes both non-prescription over-the-counter or OTC products and prescription drugs. STADA's subsidiaries sell their branded products in Germany, Austria, Belgium, China, Czech Republic, France, Ireland, Italy, Kazakhstan, the Netherlands, Portugal, Russia, Spain, Switzerland, Thailand, Ukraine, USA and Vietnam. Special Pharmaceuticals Segment Special Pharmaceuticals is the third and smallest core segment of STADA. Special pharmaceuticals at STADA include products that are distinguished from the general pharmaceutical market by specific market entry barriers, indication areas, or market and sales requirements. In the Special Pharmaceuticals segment, STADA concentrates on products that are accessible for marketing without own active ingredient research. The segment consists of drugs for cancer therapy, so-called oncology products. Strategic Acquisitions/Partnerships STADA acquired Nizhpharm OJSC, a Russian pharmaceutical company on November 8, 2004. STADA entered in to a strategic partnership with LipoNova GmbH, Hanover, in the field of tumor vaccines in fiscal 2004.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SAZ:GR €31.93 EUR -0.02

SAZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BTG PLC 603.50 GBp -2.50
Richter Gedeon Nyrt 3,949 +49.00
Impax Laboratories Inc $27.87 USD -0.29
Skyepharma PLC 245.00 GBp -0.75
Vernalis PLC 32.13 GBp 0.00
View Industry Companies
 

Industry Analysis

SAZ

Industry Average

Valuation SAZ Industry Range
Price/Earnings 15.6x
Price/Sales 0.9x
Price/Book 2.0x
Price/Cash Flow 15.5x
TEV/Sales 0.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STADA ARZNEIMITTEL AG, please visit www.stada.de. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.